Browse News

Found 154 articles

• Mitochondrial-Targeted Antioxidant Protects Genomes Against DNA Damage in Exercising Humans

  11/19/2020

  Healthy male participants who take a novel antioxidant that specifically targets the powerhouse of the cells, mitochondria, sees attenuation in exercise induced mitochondria DNA (mtDNA) damage in lymphocytes and muscle.

• KAHR Announces First Patient Dosed in Phase 1/2 Clinical Trial of DSP107, Bi-Functional CD47x41BB Candidate for the Treatment of Solid Tumors

  11/12/2020

  KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, announced dosing of the first patient in its Phase 1/2 clinical trial assessing its lead product, DSP107, a bi-functional CD47x41BB candidate for the treatment of solid tumors.

• FASENRA® eliminated oral corticosteroid use in a majority of OCS-dependent patients with asthma in PONENTE Phase IIIb trial

  10/29/2020

  FASENRA ® eliminated oral corticosteroid use in a majority of OCS-dependent patients with asthma in PONENTE Phase IIIb trial 62% of patients stopped OCS use in largest ever steroid sparing trial in severe asthma

• Immunotherapy Combo Halts Rare, Stage 4 Sarcoma in Teen

  10/15/2020

  A patient with end-stage and rapidly progressing soft-tissue cancer whose tumor did not respond to standard treatment, had a "rapid and complete response" to a novel combination of immunotherapy, according to new research published by a team of scientists from John Theurer Cancer Center at Hackensack University Medical Center

• KAHR Announces Addition of Prof. Hagop M. Kantarjian to Its Clinical Advisory Board

  10/15/2020

  Prof. Hagop M. Kantarjian, M.D., Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, has joined KAHR's clinical advisory board.

• KAHR Announces Oral Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting

  10/12/2020

  Data for DSP107, first-in-class bi-functional CD47x41BB targeting compound, to be presented on December 5, 2020

• KAHR Announces Two Key Appointments to Strengthen Leadership Team

  10/5/2020

  KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, announced that Aron Knickerbocker has been appointed Director and that Bryan Jennings has been appointed Chief Financial Officer of KAHR.

• Amunix to Present Preclinical Data on Protease-Activated HER2- and EGFR-Targeted T Cell Engagers at ESMO Virtual Congress 2020

  9/17/2020

  Data demonstrate potential of Amunix’s XPAT platform to mitigate on-target, off-tumor toxicity that has hindered success of T cell engagers in treating solid tumors

• Dr. Reddy's Laboratories announces the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, in the U.S. Market

  9/3/2020

  Dr. Reddy’s Laboratories Ltd. announced the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg and 54 mg, a therapeutic equivalent generic version of Concerta® Extended-Release Tablets, 18 mg, 27 mg, 36 mg, and 54 mg, approved by the U.S.

• Predictive Oncology Reports Second Quarter 2020 Financial Results, Provides Business Update

  8/13/2020

  Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended June 30, 2020 and provided a business update.

• Predictive Oncology Issues Letter to ShareholdersAnnual Meeting of Stockholders to be Held on September 3, 2020

  8/11/2020

  Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today issued a letter to shareholders discussing the Company’s recent accomplishments and voting recommendations from its Board of Directors for two proposals that are scheduled for shareholder vote on September 3, 2020.

• ORTIKOS™ (budesonide), the First and Only Once-Daily Dose for Treatment of Mild to Moderate Crohn’s Disease, Now Available in the U.S.

  7/29/2020

  ORTIKOS ™ (budesonide), the First and Only Once-Daily Dose for Treatment of Mild to Moderate Crohn’s Disease, Now Available in the U.S. ORTIKOS is available in one convenient pill in two dosage strengths (9mg, 6mg) for the treatment of mild to moderate active Crohn’s disease in patients 8 years and older and maintenance of clinical remission for up to three months in adults 1 Approximately 800,000 Americans are currently living with Crohn’s

• AMRA Medical and the National University of Singapore Partner to Study NAFLD in Asia

  6/30/2020

  AMRA Medical – global leader in body composition profiling – will collaborate with the National University of Singapore's (NUS) Yong Loo Lin School of Medicine on an Asian-centric study to enhance the understanding of Non-Alcoholic Fatty Liver Disease (NAFLD).

• Amunix to Present Preclinical Data on HER2- and EGFR-Targeted T Cell Engagers at AACR Virtual Annual Meeting II

  6/22/2020

  Data demonstrate potential of Amunix’s XPAT platform to significantly widen therapeutic index, and address on-target, off-tumor toxicity that has hindered application of T cell engagers to treat solid tumors Prodrug XPATs demonstrated >1000 fold increase in tolerated exposures versus traditional T cell engagers Amunix’s lead program, AMX-818, an XPAT T cell engager targeting HER2+ solid tumors, continues to progress toward the clinic MOUNTAIN VIEW, Calif., June 22, 2020 (GLOBE NEWS

• Predictive Oncology Completes Acquisition of Soluble Therapeutics and BioDtech

  6/2/2020

  Predictive Oncology Inc. (NASDAQ: POAI) (the “Company”) a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has completed the acquisition of the assets of Soluble Therapeutics, Inc. and BioDtech, Inc., each of which is a wholly-owned subsidiary of InventaBioTech, Inc.

• Association of Black Cardiologists Releases COVID-19 FAQ Watch

  4/15/2020

  Today, the Association of Black Cardiologists (ABC) issued frequently asked questions (FAQ Watch) for healthcare providers related to COVID-19.

• Incyte Partners with Artist and Patient J.G. Jones to Raise Awareness for Myeloproliferative Neoplasms (MPNs)

  2/27/2020

  Incyte announces launch of “Rare Reflections: MPNs Unmasked” as part of its ongoing efforts to raise awareness of MPNs.

• PhoreMost strengthens leadership team with two key appointments

  2/3/2020

  PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has made two appointments to strengthen its leadership team, as the Company positions itself for growth.

• Generex Biotechnology Appoints Independent Directors Craig Eagle, MD and Thomas Leonard to the NuGenerex Immuno-Oncology Board of Directors

  1/30/2020

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is proud to announce the appointments of Dr. Craig Eagle, MD and Mr. Thomas Leonard to the NuGenerex Immuno-Oncology (NGIO) Board of Directors.

• PhoreMost and Boehringer Ingelheim enter multi-project drug discovery collaboration

  1/7/2020

  PhoreMost to deploy its SITESEEKER platform to identify novel targets for Boehringer Ingelheim's discovery programmes